Added to YB: 2026-03-04
Pitch date: 2026-03-01
NKTR [neutral]
Nektar Therapeutics
-0.04%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally.
Market Cap
$1.9B
Pitch Price
$68.14
Price Target
92.70 (+36%)
Dividend
N/A
EV/EBITDA
-14.51
P/E
-8.73
EV/Sales
29.18
Sector
Pharmaceuticals
Category
growth
Nektar Therapeutics (NKTR): Thesis Update
NKTR (update): Rezpeg showed strong 52-wk durability in AD Phase 2b (EASI-100 rose to 22-30% w/ quarterly dosing), but AA trial missed primary endpoint (p=0.186/0.121) despite treatment effect doubling placebo. Excluding 4 eligibility violations = stat sig (p=0.049/0.042). Feb offering raised $300M for Phase 3, extending runway to Q2 2027. Risk-weighted PT $92.70 (+34% upside from $69) vs Oct PT $93.50. Multi-indication platform thesis narrowed but core AD opportunity intact in multi-billion market.
Read full article (6 min)